ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Inflammation Pharmacology
Ivarmacitinib reduces the need for adding/escalating medications in moderate-to-severe rheumatoid arthritis patients: a post-hoc analysis from a phase III trial
Provisionally accepted
- Qilu Hospital, Shandong University, Jinan, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Uncontrolled rheumatoid arthritis (RA) requires increasing the dosage of medications or adding combination therapies, leading to higher costs and increased risks of adverse events. This study aimed to assess the impact of ivarmacitinib, a selective Janus kinase 1 inhibitor, on the needs for adding/escalating medications in patients with moderate-to-severe RA. Methods: This was a post-hoc study from a phase III clinical trial (NCT04333771). Patients were randomized to receive ivarmacitinib 4 mg (n=189), 8 mg (n=189), or placebo (n=188) until week 24 (W24). From W24 to W52, patients with placebo switched to ivarmacitinib 4 mg, while patients with ivarmacitinib continued the initial treatment. Adding/escalating medication was defined as an increased dosage or new medication addition for RA treatments (excluding the study drug). Results: Ivarmacitinib 4 mg (7.4%) and 8 mg (5.3%) groups had significantly lower rates of adding/escalating medication compared to the placebo group (22.3%) within W24 (both P<0.001). Specifically, the ivarmacitinib groups presented lower rates of adding/escalating oral glucocorticoids (1.1% and 0.5%, versus 5.9%) and non-steroidal anti-inflammatory drugs (6.9% and 4.2%, versus 20.2%) than the control group within W24. No statistical significance was observed between groups in adding/escalating intravenous/intramuscular corticosteroids, conventional synthetic disease-modifying antirheumatic drugs, or systemic immunosuppressants. From W24 to W52, the rates of adding/escalating medications remained low in ivarmacitinib 4 mg (4.2%) and 8 mg (3.2%) groups; the switched group showed a reduced rate of adding/escalating medications (12.2%). Conclusion: Ivarmacitinib significantly reduces the need for adding/escalating medications compared to placebo, thereby potentially decreasing treatment burden. However, the post-hoc, exploratory nature of this study requires further validation for the findings.
Keywords: Ivarmacitinib, Rheumatoid arthritis, high selective JAK inhibitor, adding/escalatingmedication, Phase III trial
Received: 11 Aug 2025; Accepted: 30 Oct 2025.
Copyright: © 2025 Liu, Li and Song. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Huaxiang Liu, liuhx0016@163.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.